A Unified Primary Care Approach for the Management of Insomnia and Confusion Using the Clinical Pathway

Megumi Kabeya (✉ m-kabeya@hospy.or.jp)

Nagoya Memorial Hospital <https://orcid.org/0000-0001-9755-0356>

Shu Yuasa

Nagoya Memorial Hospital

Kenji Ina

Shinseikai Dai-ichi Hospital

Chiaki Tokoro

Nagoya Memorial Hospital

Yosuke Kubota

Nagoya City University Hospital

Satoshi Kayukawa

Nagoya Memorial Hospital

Research Article

Keywords: delirium, clinical pathway, insomnia and confusion, falls, benzodiazepines

Posted Date: February 21st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-955231/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

Delirium -characterized by an acute or subacute decline in cognitive functioning- and confusion are risk factors for falls and its related injuries. Therefore, we designed a unified clinical pathway to reduce the risk of delirium among hospitalized patients.

Methods

A unified approach of pharmacotherapy for managing insomnia and confusion, which is subdivided based on the patients' age (<70 versus ≥ 70 years) and presence of diabetes mellitus, was implemented in Nagoya Memorial Hospital, Japan. Risk factors for delirium were assessed via a multidisciplinary approach. For older high-risk patients, suvorexant or trazodone was prophylactically prescribed to promote sleep. If delirium occurred, either quetiapine or perospirone was administered prior to the usage of risperidone or haloperidol. The amounts of prescribed sleep inducers and antipsychotic agents were examined. The application rate of the clinical pathway and incidence of falls were compared before and after its introduction.

Results

The application of a unified approach significantly decreased the prescribed amounts of benzodiazepines and may be associated with the reduced incidence of falls among inpatients.

Conclusions

A clinical pathway assisted the selection of sleep inducers and antipsychotic agents. This is useful for managing elderly patients safely by preventing delirium and subsequent falls.

Background

Delirium is characterized by an acute or subacute decline in cognitive functioning and fluctuating disturbances in attention, circadian rhythm, emotion, and psychomotor functions¹. Risk factors for delirium are classified into predisposing and precipitating factors². Common predisposing factors include advanced age (≥ 70 years), comorbidities, and dementia. Precipitating factors include infections, sleep disruptions, and the usage of drugs, such as sedative hypnotics^{3, 4}. Benzodiazepines have been established a principal contributor toward delirium and patient falls⁵. Furthermore, delirium and confusion are well established risk factors for patient falls and related injuries⁶, and are associated with longer hospital stays^{2, 7} and increased caregiver burden^{8, 9}. Most delirium presentations are preceded by sleep disturbances and restlessness⁴. In Nagoya Memorial Hospital, prescriptions for insomnia and delirium were dependent on the relevant attending physician. Therefore, the nursing observation items varied greatly among hospitalized patients. Accordingly, a unified clinical pathway of pharmacotherapy for insomnia and confusion was developed to promote a standardized approach to treating delirium.

Methods

We designed a clinical pathway for managing insomnia and confusion with reference to the Japanese Psycho-Oncology Society (JPOS) and Japanese Association of Supportive Care in Cancer (JASCC) clinical guidelines for delirium¹⁰. Patients were then subdivided according to age (<70 versus ≥70 years) and the presence of diabetes mellitus as shown in Table 1. The comments described in the clinical pathway included the half-life of each drug and precautions as a reference for additional administration and the onset of effects. Prior to issuing the clinical pathway, nurses, pharmacists, and attending physicians checked for the presence of benzodiazepines, delirium-inducing drugs, and Parkinson's disease. The specific clinical pathway for each patient was selected from four options. As described in Table 2, outcomes were evaluated as 1st grade, ("Excellent night's sleep"), 2nd grade ("The outbreak of delirium is controlled"), and 3rd grade ("Fall prevention"). Table 3 showed that a unified format of nursing observation items was adopted to eliminate the disparities of nursing care provision.

Table 1
A clinical pathway of pharmacotherapy for insomnia and confusion

≥70 y; DM(-)	<70 y; DM(-)	≥70 y; DM(+)	<70 y; DM(+)
Quetiapine (25mg) 1tablet Confusion 1st choice t1/2 3h	Quetiapine (25mg) 1tablet Confusion 1st choice t1/2 3h	Perospirone (4mg) 1tablet Confusion 1st choice t1/2 2.3h	Perospirone (4mg) 1tablet Confusion 1st choice t1/2 2.3h
Risperidone (1mg) 1packet Confusion 2nd choice t1/2 21h ※kidney function attention	Risperidone (1mg) 1packet Confusion 2nd choice t1/2 21h ※kidney function attention	Risperidone (1mg) 1packet Confusion 2nd choice t1/2 21h ※kidney function attention	Risperidone (1mg) 1packet Confusion 2nd choice t1/2 21 h ※kidney function attention
Suvorexant (15mg) 1tablet Insomnia 1st choice t1/2 10h p. o. after dinner early, assessment everyday medication	Suvorexant (20mg) 1tablet Insomnia 1st choice t1/2 10h p. o. after dinner early, assessment everyday medication	Suvorexant (15mg) 1tablet Insomnia 1st choice t1/2 10h p. o. after dinner early, assessment everyday medication	Suvorexant (20mg) 1tablet Insomnia 1st choice t1/2 10h p. o. after dinner early, assessment everyday medication
Trazodone (25mg) 1tablet Insomnia 2nd choice t1/2 6h	Eszopiclone (1mg) 2tablets Insomnia 2nd choice t1/2 6h	Trazodone (25mg) 1tablet Insomnia 2nd choice t1/2 6h	Eszopiclone (1mg) 2tablets Insomnia 2nd choice t1/2 6h
Quetiapine (25mg) 1tablet (Delirium high risk group with the confusion) Insomnia 1st choice t1/2 3h	Quetiapine (25mg) 1tablet (Delirium high risk group with the confusion) Insomnia 1st choice t1/2 3h		

This pathway is based on the patients' age (<70 versus ≥70 years) and the presence of diabetes mellitus (DM).

≥70 y; DM(-)	<70 y; DM(-)	≥70 y; DM(+)	<70 y; DM(+)
Haloperidol (5mg) 1A saline water100mL 1V in 30 minutes, 202mL/h Insomnia□confusion 1st choice t1/2 14h sleep stop and go	Haloperidol (5mg) 1A saline water100mL 1V in 30 minutes, 202mL/h Insomnia□confusion 1st choice t1/2 14h sleep stop and go	Haloperidol (5mg) 1A saline water100mL 1V in 30 minutes, 202mL/h Insomnia□confusion 1st choice t1/2 14h sleep stop and go	Haloperidol (5mg) 1A saline water100mL 1V in 30 minutes, 202mL/h Insomnia□confusion 1st choice t1/2 14h sleep stop and go
Haloperidol (5mg) 0.5A Flunitrazepam (2mg) 0.5A saline water100mL 1V in 60 minutes, 101mL/h Insomnia□confusion 2nd choice t1/2 14h sleep stop and go ECG needed	Haloperidol (5mg) 0.5A Flunitrazepam (2mg) 0.5A saline water100mL 1V in 60 minutes, 101mL/h Insomnia□confusion 2nd choice t1/2 14h sleep stop and go ECG needed	Haloperidol (5mg) 0.5A Flunitrazepam (2mg) 0.5A saline water100mL 1V in 60 minutes, 101mL/h Insomnia□confusion 2nd choice t1/2 14h sleep stop and go ECG needed	Haloperidol (5mg) 0.5A Flunitrazepam (2mg) 0.5A saline water100mL 1V in 60 minutes, 101mL/h Insomnia□confusion 2nd choice t1/2 14h sleep stop and go ECG needed
This pathway is based on the patients' age (<70 versus ≥70 years) and the presence of diabetes mellitus (DM).			

Table 2
Outcomes and indications

Name	Insomnia/ confusion(≥ 70 y $\square$ DM-)			
Phase	Day1	Day2	Day3	Day4
Date	$\square$	$\square$	$\square$	$\square$
Outcome	1. Excellent night's sleep			
	2. The outbreak of delirium is controlled			
	3. Fall prevention			
Indication	Indication			
	When using benzodiazepines, report to the attending physician.			
	$\square \geq 70$ years: benzodiazepines are generally prohibited			
	Indication			
	Parkinsonism (+) (-)			
	Haloperidol: Parkinson's disease is contraindicated			
	Indication			
	DM (+) (-)			
	Quetiapine: DM is contraindicated			
	Indication			
	Delirium-inducing drugs (+) (-)			
	For example: benzodiazepines, H2 blocker			

Table 3
A unified format of nursing observation items

Evaluation items	Estimation method
SpO ₂	Measured value
Nocturnal awakening	+, -, ±
Early morning awakening	+, -, ±
Constipation	+, -, ±
Appetite	+, -, ±
Nausea	+, -, ±
Somnolence	+, -, ±
Excitation	+, -, ±
Restlessness	+, -, ±
Dangerous behavior (falls)	+, -, ±
Depression	+, -, ±
Environmental adjustment (setting a calendar, clock, or photograph)	☒, ×
Toilet guidance	☒, ×
Induction of life rhythm	☒, ×

We examined the prescribed amounts of hypnotics and antipsychotics for inpatients between 2012 and 2019. We compared the application rates, the usage ratio of the above-mentioned drugs, and the fall rates among the inpatients before and after the introduction of the current clinical pathway for insomnia and confusion. The prescribed amounts of benzodiazepines and Z-drugs were converted into those of diazepam (DZP conversion), and the amounts of antipsychotics were converted into those of chlorpromazine (CP conversion). [11] This retrospective study was approved by the Research Ethics Committee of Nagoya Memorial Hospital (approval No. 2020-017) and conducted in accordance with the Declaration of Helsinki.

The data analysis was primarily performed using descriptive statistics. The results of a stratified analysis were compared using Fisher's exact test or Mann-Whitney U test between two groups, and Bonferroni's test among the three groups. All *p*-values were two-sided, and *p*-values of 0.05 or less were considered statistically significant. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). Specifically, it is a modified version of the R commander, designed to add statistical functions frequently used in biostatistics [12].

Results

Prescribed amounts of hypnotics and antipsychotic drugs were shown in Table 4. Regarding sedative hypnotics, the number of prescriptions of brotizolam consistently decreased, while that of suvorexant and trazodone reciprocally increased during the study period. For antipsychotics, the number of prescriptions of risperidone (1mg) decreased in 2019, while that of quetiapine increased from 2016 and reached a plateau. Perospirone was not prescribed until 2016; however, the prescribed amounts then gradually increased. Among injection formulations, the prescribed amounts of hydroxyzine decreased, while that of haloperidol increased. The application of clinical pathway significantly reduced the usage ratios of benzodiazepines, Z-drugs, and hydroxyzine. Furthermore, it increased the usage ratios of suvorexant and trazodone (Figure 1). There was a notable decrease in the ratio of antipsychotics overall due to clinical pathway usage (21.2% versus 15.6%). The same trend was observed among elderly patients (Figure 2).

Table 4 Prescribed amounts of hypnotics and antipsychotic drugs

		Year							
Drugs		2012	2013	2014	2015	2016	2017	2018	2019
Benzodiazepines	Brotizolam 0.25mg	19415	17648	15706	14095	13119	9924	6939	5147
	Flunitrazepam 2mg	94	101	340	74	152	120	125	291
Z-drugs	Zolpidem 10mg	2286	2213	3133	2986	2282	1927	1338	2126
	Eszopiclone 1mg					301	2034	3416	2255
Hydroxyzine 25mg		3283	2537	2742	1761	1567	1932	1375	905
Suvorexant	Suvorexant 15mg				17	1114	1515	5796	11811
	Suvorexant 20mg				38	321	203	522	924
Trazodone 25mg		766	942	822	294	1035	430	1475	4417
Ramelteon 8mg		36	48	242	349	771	712	613	1057
Antipsychotics	Quetiapine 25mg	216	260	852	510	1296	1562	2480	2161
	Perospirone 4mg						44	289	322
	Risperidone 1mg	1742	2191	1494	2124	2338	2252	1906	1110
	Haloperidol 5mg	538	471	486	775	664	924	956	1181

The average amounts of prescribed hypnotics and antipsychotics per month were compared before and after the introduction of a unified clinical pathway for insomnia and confusion in Table 5. The average amounts of prescribed hypnotics (DZP) and antipsychotics (CP) per month were reduced after the introduction of a unified clinical pathway for insomnia and confusion. The same trend was observed among elderly patients, as shown in Table 6.

Table 5 The comparison of average amounts of prescribed hypnotics and antipsychotics per month before and after

Drugs	Before			After			p-value
Hypnotics (DZP conversion)	16485.4	±	884.1	9123.8	±	343.4	#a
Benzodiazepines (DZP conversion)	15989.1	±	898.5	8614.1	±	338.7	#a
Z-drugs (DZP conversion)	496.2	±	44.3	509.6	±	30	
Hydroxyzine (mg)	3597.2	±	163	1861.1	±	114.1	#a
Suvorexant (mg)	3157.1	±	467	14609.7	±	777.1	#b
Trazodone (mg)	1035.4	±	237.1	7743.8	±	748.9	#b
Ramelteon (mg)	419.1	±	33.8	639.1	±	116.3	
Antipsychotics (CP conversion)	26475.6	±	1362.9	20754.1	±	1622.3	#a

Before: January 2017 – June 2018

After: July 2018 – December 2019

DZP conversion: The prescribed amounts of benzodiazepines and Z-drugs were converted into those of diazepam.

CP conversion: The amounts of antipsychotics were expressed in terms of the amounts of chlorpromazine.

#a indicates a significant decrease and #b indicates a significant increase compared to the prescription amounts before the introduction of a unified clinical pathway for insomnia and confusion; $p < 0.05$ (Mann-Whitney U test)

Table 6 The comparison of ≥ 70 years average amounts of prescribed hypnotics and antipsychotics per month

Drugs	Before			After			p-value
Hypnotics (DZP conversion)	10210.3	±	691.6	5613.7	±	285.9	#a
Benzodiazepines (DZP conversion)	9851.9	±	700.8	5242.5	±	281.8	#a
Z-drugs (DZP conversion)	358.3	±	36.9	371.2	±	30.0	
Hydroxyzine (mg)	2637.5	±	131.6	1169.4	±	89.7	#a
Suvorexant (mg)	2320.7	±	407.9	12418.6	±	718.1	#b
Trazodone (mg)	718.1	±	191.5	6331.9	±	570.1	#b
Ramelteon (mg)	398.2	±	28.0	525.3	±	84.4	
Antipsychotics (CP conversion)	21399.4	±	1574.2	17760.5	±	1583.5	0.0685

Before: January 2017 – June 2018

After: July 2018 – December 2019

DZP conversion: The prescribed amounts of benzodiazepines and Z-drugs were converted into those of diazepam.

CP conversion: The amounts of antipsychotics were expressed in terms of the amounts of chlorpromazine.

#a indicates a significant decrease and #b indicates a significant increase compared to the prescription amounts before the introduction of a unified clinical pathway for insomnia and confusion; $p < 0.05$ (Mann-Whitney U test)

Application rate of the clinical pathway was highest in the department of neurosurgery, followed by gastrointestinal medicine, as shown in Table 7. As the application rates increased, the fall rates decreased in both departments (Figure 3). The fall rates was significantly reduced in neurosurgery (2017; 12.3% vs 2019; 4.6%, 2018; 10.2% vs 2019; 4.6%, Bonferroni's test).

Table 7 The application rates of a unified clinical pathway for insomnia and confusion by clinical department.

Departments	July 2018 – December 2018			January 2019 – December 2019		
	All	Applied	Application rate (%)	All	Applied	Application rate (%)
neurosurgery	112	46	41.1	188	118	62.8
gastrointestinal medicine	386	138	35.8	692	318	46
nephrology	62	18	29	147	59	40.1
cardiology	299	36	12	534	123	23
urology	117	8	6.8	277	51	18.4
medical oncology/hematology	364	39	10.7	758	116	15.3
surgery	108	8	7.4	274	40	14.6
metabolism and endocrinology	79	1	1.3	156	14	9
respiratory medicine	195	8	4.1	362	27	7.5
otorhinolaryngology	16	0	0	28	2	7.1
orthopedics	216	7	3.2	466	17	3.6

Discussion

Delirium is extremely distressing for patients, their families, and their professional caregivers^{8, 9}. We used suvorexant, a selective orexin receptor antagonist, as the primary choice of hypnotics in the current clinical pathway¹³. As a secondary choice, the Z-drugs eszopiclone and trazodone were administered for patients aged < 70 and ≥ 70 years, respectively. Thus, the prescribed amounts of benzodiazepines significantly decreased. However, it should be noted that suvorexant is metabolized by cytochrome P450 (CYP) 3A4. Since approximately 75% of marketed drugs are metabolized by CYP and approximately half of these are metabolized by CYP3A4¹⁴, the concomitant drug must be investigated to determine the drug interaction.

For the treatment of restlessness, quetiapine was selected due to its short half-life¹⁵. Perospirone was administered to the patients with diabetes mellitus, since quetiapine is contraindicated for this disorder¹⁶. While risperidone also has a short half-life of 4 hours, its active metabolite is excreted through the kidney, which has a half-life of 20 to 24 hours and may increase depending on renal function¹⁷. Renal functions often decline in elderly patients; therefore, risperidone was considered as a second choice. The application of the present clinical pathway significantly decreased the usage ratio of antipsychotics overall. Additionally, higher application rates of the clinical pathway were associated with lower fall rates. These findings suggest that the proper choice of hypnotics is helpful for the prevention of confusion and subsequent falls.

Prior to the clinical pathway introduction, each doctor prescribed hypnotics and antipsychotics based on their own experiences. It was thus difficult for the multi-disciplinary staff to collaborate on the management of insomnia and confusion. Drug information, including half-life and precautions, were available upon commencing the clinical pathway. These were provided in the electronic medical record, enabling nursing staff to consult with it at any

time. Ward pharmacists held a study session in each ward to diffuse knowledge on hypnotics and antipsychotics among the staff, which enhanced communication and prompted inquiry from the nurses. Accordingly, the doctors were confident in the use of the clinical pathway. Currently, there are several departments in which the clinical pathway for insomnia and confusion can be routinely applied for inpatients. When there is a lack of instructions for the management of insomnia and confusion on admission, nursing staff often request physicians to use this clinical pathway for high-risk patients.

Recently, pharmacovigilance data have been reported in palliative care^{18, 19}. Furthermore, non-pharmacologic interventions such as reorientation, maintaining hydration and nutrition, early mobilization, and hearing and visual adaptations are extremely effective in decreasing the occurrence of delirium among elderly persons^{20, 21}. The usage of the clinical pathway, along with interdisciplinary involvement, further improves the quality of sleep. This may eventually reduce the usage of antipsychotics and decrease the incidence of falls, enhancing daytime activity levels and the efficacy of rehabilitation.

Conclusions

A clinical pathway of pharmacotherapy for insomnia and confusion ensures appropriate prescription of sleep inducers and antipsychotics. This may contribute to the safe management of hospitalized elderly patients by preventing delirium and subsequent falls.

List Of Abbreviations

DZP: diazepam

CP: chlorpromazine

JPOS: Japanese Psycho-Oncology Society

JASCC: Japanese Association of Supportive Care in Cancer

CYP: cytochrome P450

Declarations

Ethics approval and consent to participate

The protocol of this study was approved by the ethics committee of Nagoya Memorial Hospital (approval No. 2020-017) and conducted in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

Author contributions

MK and KI wrote the manuscript. MK, SK, and YK reviewed the medical records. MK and SY performed the computed analyses. All authors read and approved the final manuscript.

Authors' information

Affiliations

Department of Pharmacy, Nagoya Memorial Hospital, 4-305 Hirabari, Tenpaku-ku, Nagoya, 468-8520, Japan

Megumi Kabeya

Department of Pharmacy, Nagoya Memorial Hospital, 4-305 Hirabari, Tenpaku-ku, Nagoya, 468-8520, Japan

Shu Yuasa

Department of Internal Medicine, Shinseikai 1st Hospital, 1302 Takamiya-cho, Tenpaku-ku, Nagoya, 468-8520, Japan

Kenji Ina

Nursing Department, Nagoya Memorial Hospital, 4-305 Hirabari, Tenpaku-ku, Nagoya, 468-8520, Japan

Chiaki Tokoro

Division of Psycho-oncology and Palliative Care, Nagoya City University Hospital, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan

Yosuke Kubota

Department of Hematology, Nagoya Memorial Hospital, 4-305 Hirabari, Tenpaku-ku, Nagoya, 468-8520, Japan

Satoshi Kayukawa

Corresponding author

Correspondence to Megumi Kabeya

References

1. Sharon K, Inouye, Rudi GJ, Westendorp, Jane S, Saczynski. Delirium in elderly people. *Lancet*. 2014;383:911–22.
2. Marcantonio ER. Delirium in Hospitalized Older Adults. *N Engl J Med*. 2017;377:1456–66.

3. Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. *J Clin Oncol*. 2012; 30: 1206-14.
4. Maldonado JR. Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure. *Int J Geriatr Psychiatry*. 2018;33:1428-57.
5. Soyka M. Treatment of Benzodiazepine Dependence. *N Engl J Med*. 2017;376:1147–57.
6. O'Mahony R, Murthy L, Akunne A, Young J. Guideline Development Group. Synopsis of the National Institute for Health and Clinical Excellence guideline for prevention of delirium. *Ann Intern Med*. 2011;154:746–51.
7. Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson JL, Pun BT, et al. Long-term cognitive impairment after critical illness. *N Engl J Med*. 2013;369:1306–16.
8. Morita T, Akechi T, Ikenaga M, Inoue S, Kohara H, Matsubara T, et al. Terminal delirium: recommendations from bereaved families' experiences. *J Pain Symptom Manage*. 2007;34:579–89.
9. Bruera E, Bush SH, Willey J, Paraskevopoulos T, Li Z, Palmer JL, *et al*. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. *Cancer*. 2009; 115: 2004-12.
10. Matsuda Y, Tanimukai H, Inoue S, Inada S, Sugano K, Hasuo H, et al. JPOS/JASCC clinical guidelines for delirium in adult cancer patients: a summary of recommendation statements. *Jpn J Clin Oncol*. 2020;50:586–93.
11. Inada T, Inagaki A. Psychotropic dose equivalence in Japan. *Psychiatry Clin Neurosci*. 2015;69:440–7.
12. Kanda Y. Investigation of the freely available easy-to-use software “EZ” (Easy R) for medical statistics. *Bone Marrow Transplant*. 2013;48:452–8.
13. Hatta K, Kishi Y, Wada K, Takeuchi T, Ito S, Kurata A, et al. Preventive Effects of Suvorexant on Delirium: a Randomized Placebo-Controlled Trial. *J Clin Psychiatry*. 2017;78:e970–9.
14. Lolodi O, Wang YM, Wright WC, Chen T. Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery. *Curr Drug Metab*. 2017;18:1095–105.
15. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. *J Clin Psychiatry*. 2002;63(Suppl 13):5–11.
16. Polcwiartek C, Vang T, Bruhn CH, Hashemi N, Rosenzweig M, Nielsen J. Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. *Psychopharmacology*. 2016;233:3663–72.
17. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. *Br J Clin Pharmacol*. 2008;66:629–39.
18. Crawford GB, Agar MM, Quinn SJ, Phillips J, Litster C, Michael N, et al. Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium. *J Palliat Med*. 2013;16:1335–41.
19. Okuyama T, Yoshiuchi K, Ogawa A, Iwase S, Yokomichi N, Sakashita A, et al. Current Pharmacotherapy Does Not Improve Severity of Hypoactive Delirium in Patients with Advanced Cancer: Pharmacological Audit Study of Safety and Efficacy in Real World (Phase-R). *Oncologist*. 2019;24:e574–82.
20. Hsieh TT, Yue J, Oh E, Puelle M, Dowal S, Trivison T, et al. Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis. *JAMA Intern Med*. 2015;175:512–20.
21. Lawlor PG, Rutkowski NA, MacDonald AR, Ansari MT, Sikora L, Momoli F, et al. A Scoping Review to Map Empirical Evidence Regarding Key Domains and Questions in the Clinical Pathway of Delirium in Palliative

Figures

Figure 1

The comparison of the usage ratio of hypnotics and antipsychotics before and after the introduction.

Before: January 2017 – June 2018

After: July 2018 – December 2019

#a indicates a significant decrease and #b indicates a significant increase compared to the usage ratio at baseline; $p < 0.05$ (Fisher's exact test).

Figure 2

Before

After

- Benzodiazepine ■ Z-drug ▨ Hydroxyzine 25mg ■ Suvorexant
- ▤ Trazodone 25mg ▦ Ramelteon 8mg □ Antipsychotic

Figure 2

The comparison of the usage ratio of hypnotics and antipsychotics in ≥ 70 years.

Before: January 2017 – June 2018

After: July 2018 – December 2019

#a indicates a significant decrease and #b indicates a significant increase compared to the usage ratio at baseline; $p < 0.05$ (Fisher's exact test).

Figure 3

Figure 3

Chronological changes in fall rates and application rates of a unified clinical pathway.

A: Department of neurosurgery

B: Department of gastrointestinal medicine

#a indicates a significant difference compared to fall rates in 2017. #b indicates a significant difference compared to fall rates in 2018. $p < 0.05$ (Bonferroni's test).